BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Call Transcript
November 3, 2025
Earnings Call Speaker Segments
Good day, everyone, and thank you for being on this BioCryst conference call, where we're discussing our corporate update along with the financial results from Q3 of 2025. Joining me today are Jon Stonehouse, our CEO; Charlie Gayer, who serves as President and Chief Commercial Officer; Dr. Bill Sheridan, our Chief Development Officer; and Babar Ghias, our Chief Financial Officer. A press release and a slide deck about today's announcements are available in the Investor Relations portion of our website. During this call, we may make forward-looking statements — for example, anticipated financial results, unaudited and forward-looking financial information, and the company's future performance and/or achievements. Those statements involve known and unknown risks and uncertainties that might cause actual results, performance, or achievements to differ materially from any future results or performance expressed or implied here. For additional detail, including a comprehensive review of these risks, please refer to Slide 2 of the presentation. In addition, non-GAAP financial measures are included in this conference call. For a reconciliation of those non-GAAP measures to the most directly comparable GAAP financial measure, please consult the earnings press release. Non-GAAP operating expenses, which exclude stock-based comp and transaction-related costs, came in at roughly $108 million in the third quarter of 2025, compared with approximately $92 million in the third quarter of 2024. With that, I'll turn the call over to Jon Stonehouse.
Thanks, Nick. We're really happy to share that we've delivered another robust quarter this year. To begin with ORLADEYO, revenue keeps climbing strongly compared with the same period a year ago, and that's on top of an already expanding revenue base — we're well along the path toward $1 billion at peak. Charlie will walk everyone through the specifics, since this marked the first quarter facing new competition, and just as we anticipated, underlying growth remains solid and our prescriber base keeps getting bigger. Turning to the next item, we completed the divestiture of our European business and cleared our Pharmakon debt; that did more than tidy up the balance sheet — it left us in a really strong financial spot, producing operating profit along with positive cash flow. Babar will go into further detail about where we stand financially. We're likewise advancing our pipeline, and we anticipate early data that ought to offer a first look at activity and dose from the DME program, with plans to share that early next year. Should those results look promising, we've also decided that because this program sits outside the rare disease space we focus on, we'll pursue a spin-out or a partnership to place it with a party better positioned to move it forward. On BCX17725, Bill will present encouraging results from our healthy volunteer trial that demonstrate the drug does reach the skin after IV administration. That matters because it's precisely where the target for Netherton syndrome resides, and with such a potent inhibitor in BCX17725, we're eager to learn, in Netherton syndrome patients, what impact it has on the disease. Enrollment has been moving somewhat slower than we'd planned, so we now anticipate early data from a small number of Netherton syndrome patients later in Q1 of next year. Finally, after announcing last month our proposed acquisition of Astria, with an expected close in Q1 next year, we're thrilled to bring a late-stage asset, navenibart, into our pipeline, allowing us to apply our HAE know-how and offer patients a new treatment option whose administration burden is low. So as you can see, things have been quite busy since our last quarterly earnings report, and this year is on track to be another exceptional one for performance at our company; with that, I'll hand things over to Charlie.
Thanks, Jon. We moved into 2025's last quarter carrying solid momentum; our ORLADEYO revenue outlook is being lifted to a range of $590 million to $600 million for the year, and that holds true even after the European operations sale wrapped up on October 1; plus, there are thrilling prospects right around the corner with the ORLADEYO granules launch for kids who have HAE and the Astria acquisition. For HAE patients, ORLADEYO remains the prophylaxis therapy that stands apart the most. An oral option for preventing attacks is what most HAE patients would choose. This is something physicians understand, and their confidence in ORLADEYO is strong. Despite 2 new prophylaxis products having recently hit the market, giving patients the possibility of injectable dosing once a month, ORLADEYO's new prescriptions kept up the same robust rate we've observed across the past 2 years. In fact, we came in slightly above the new patient prescription count from the third quarter of last year. We've also kept growing our base of ORLADEYO prescribers, adding 64 new prescribers in the U.S., which beats the average from the past 8 quarters. Patient retention showed the same long-established patterns, and we closed the quarter at an 82% paid patient rate, exactly matching the usual second half pattern relative to the first half of the year. As ever, these great results make us very happy, though they don't come as a surprise. Our extensive insight and market simulation work consistently forecast that ORLADEYO's growth would be unaffected by new competition; we refreshed that work during the summer, and the 2025 figures came out nearly the same as the 2024 figures, as Slide 8 in today's presentation shows. With ORLADEYO granules expected to be added on top of the strong growth trends ORLADEYO capsules already have, our market simulation keeps projecting $1 billion in peak revenue for BioCryst in 2029, even following the sale of our European business. What the analysis shows is that new injectable therapies mostly go up against injectable therapies that already exist. That's the reason we feel such enthusiasm about the chance to bring navenibart into our portfolio. With navenibart, we could offer the lowest burden and most differentiated injectable prophylactic therapy, alongside a long-time leading oral therapy, greatly broadening our capacity to help patients in the HAE community. We anticipate navenibart will fuel double-digit HAE revenue growth well into the 2030s once ORLADEYO revenue hits a steady plateau. And we anticipate managing costs by leveraging the very same rare disease commercialization engine that made ORLADEYO so successful. Today, I'm also delighted to share that Ron Dullinger will take over from me as Chief Commercial Officer when I step into the CEO role on January 1. Ron headed the sales team at ViroPharma through the early days of CINRYZE commercialization. That drug reshaped the HAE treatment paradigm at the time, yet Ron always understood that an oral therapy was what many patients truly desired, and he wanted to help make that a reality. Ron came aboard in 2019 to build and lead the U.S. team — U.S. Our sales organization handled the ORLADEYO introduction. And from 2022 onward, he's been the General Manager for our U.S. and Americas operations, building a team culture that cares deeply and stays genuinely committed to serving patients, while also pushing relentlessly to get better. You don't often see those two things together, and the results have been remarkable. I'm eager to see what our commercial group accomplishes with Ron at the helm. As we anticipate supporting more and more HAE patients, our enthusiasm keeps building around the possibility of helping those with Netherton syndrome. I'll hand things to Bill so he can walk us through where we stand with BCX17725.
Thanks, Charlie. I'm quite happy to be able to discuss a few results from the Phase I trial we're still running for BCX17725, our new investigational KLK5 inhibitor that's intended to substitute for the functions of the natural inhibitor that people with Netherton syndrome lack. There are several objectives built into this study: first, getting a handle on BCX17725's initial safety profile; second, measuring how much of it reaches the bloodstream by looking at serum drug levels; third, looking at how the drug distributes into the epidermis. That last point matters a great deal, since the target enzyme, KLK5, is found there. Fourth, we're evaluating whether it might produce early treatment effects on the signs and symptoms of Netherton syndrome. We intend to start that in a limited group of individuals with NS as part of the study's Part 3. To this point, the trial has progressed across multiple cohorts of healthy participants, and those groups have gotten either one dose or several doses of the investigational drug. That provides us with insight into goals 1 through 3. BCX17725's dose has been escalated gradually, reaching 12 milligrams per kilogram delivered by IV infusion. During the multiple ascending dose segment, 3 administrations occurred on a schedule of once every 2 weeks. So far in this study, BCX17725 has demonstrated a good safety profile and has been well tolerated, and we haven't seen any safety signals. An early review of systemic exposure profiles supports moving forward with testing dose schedules going as long as every 2 weeks. On the slide that goes with this, you'll find a few representative pictures taken from skin biopsies that were gathered before and after dosing in healthy subjects. These are small punch biopsies, taken with local anesthetic, which are then processed for imaging. The pictures you're seeing were produced using a method called immunofluorescence microscopy. You use antibodies that attach in a targeted way to whichever protein you're trying to find — here, that's the drug BCX17725. After that, those bound groups get picked up by secondary antibodies that have been chemically linked to a fluorochrome. A fluorochrome is a substance that gives off light, usually when exposed to ultraviolet or near-ultraviolet wavelengths. So wherever the drug sits within the tissue sample, we're able to observe a particular hue determined by which fluorochrome was chosen, and a stronger glow corresponds to a greater amount of drug present. We can additionally employ fluorochromes of other colors to highlight things like cell nuclei. Even though this approach causes only slight tissue damage, there's a cap on how many biopsies we're able to collect. We therefore chose to take a biopsy at baseline before the first dose, using it as a control, along with another biopsy taken five hours following the final dose of the drug. In the images of biopsy samples shown, which came from a representative healthy volunteer in the cohort receiving multiple doses of 12 milligrams per kilogram, DNA appears in blue within cell nuclei while the drug shows up in green within the extracellular matrix. Looking at the sample taken before dosing, you can see the loose dermis, where bright blue nuclei are widely spaced, and the dense epidermis, where nuclei are tightly packed, with a very faint green signal resulting from nonspecific binding by the assay reagents. When you look at the sample taken after dosing, a clear difference is visible, with green fluorescence that is much brighter. The blue nuclei can serve as your reference point. Once the dose was given, the drug had saturated the loose connective tissue within the dermis and spread across the entire epidermis. Those results matter a great deal. It managed to cross the epidermal basement membrane and reach the extracellular matrix present in every epidermal layer. Once the drug reaches the epidermis, it can get at KLK5, the target enzyme, in individuals who have Netherton syndrome. Both our investigators and ourselves are genuinely thrilled about what these data show, and over the next few months we anticipate bringing patients with NS into the study. At this point I want to hand things over to Babar, who will take you through how we're doing financially.
Thank you, Will. Serving as BioCryst's CFO for a complete quarter for the first time proved quite busy, filled with multiple notable milestones that I feel set us up nicely for expansion and profitability ahead. On October 1, the divestiture of our European operations closed successfully, giving an instant lift to our finances and letting us pay off our Pharmakon debt entirely. Throughout Q3, we put substantial effort into a highly strategic, transformative move to acquire Astria Therapeutics — announced just last month — which should bolster our standing in HAE and cement a double-digit growth path for our portfolio across the coming decade. In connection with this proposed deal, we also focused on locking in a strategic financing arrangement with Blackstone at a very appealing cost of capital. Once the Astria purchase closes, anticipated in Q1 2026, we'll draw up to $400 million in cash through this facility. Yet none of it would have been achievable without ORLADEYO's ongoing strength and our bettering operational results. Please look at our Q3 financials in today's press release, though I'd like to spend a moment detailing a few of these wins and how they shape our path. Revenue for ORLADEYO totaled $159.1 million, a 37% rise versus the prior year. Within that ORLADEYO figure, $141.6 million, or 89%, was generated in the U.S. As Charlie mentioned, we keep witnessing robust momentum in our business even with the approvals announced recently. Non-GAAP operating expenses, leaving out stock-based comp and transaction-related costs, reached roughly $118 million in Q3 2025, compared with about $92 million in Q3 2024. Part of that rise stemmed from ongoing R&D investment, which remains a priority for us. As Bill noted, we're quite enthusiastic about what these programs could deliver. We've also decided strategically to look for partners for our DME program once we review initial patient data, given our sharpened emphasis on rare diseases and directing capital toward programs where we can generate the greatest value. Non-GAAP operating profit, excluding stock-based compensation expense and transaction-related costs, came to $51.7 million in Q3 2025, a 107% year-over-year jump, as we keep gaining from considerable operating leverage. Non-GAAP net income for the quarter hit $35.6 million, yielding non-GAAP EPS of $0.17 per share; we ended the quarter in a strong position with $269 million in cash, including cash held for sale by European entities. Our robust cash flow profile let us prepay $50 million on our Pharmakon term loan in Q3. And when the European business sale closed, we likewise settled the roughly $200 million remaining balance on that term loan. On a pro forma basis, accounting for these changes, our cash stands at approximately $294 million with 0 term debt. Given the strong cash flow we expect to generate, we foresee hitting $1 billion in cash during 2029. Even so, we'll keep assessing a range of ways to deploy capital that create value for our shareholders, similar to the proposed purchase of Astria Therapeutics we announced not long ago. Once the deal closes, we'll also look into a European license covering navenibart as well as strategic possibilities for the STAR-0310 program, which could bring additional upside. Turning to guidance. Charlie has already mentioned the revenue outlook, and in addition, we're bringing our non-GAAP OpEx guidance down to $430 million to $440 million, compared with the $440 million to $450 million we originally guided. Thanks to the European divestiture, we have the chance to keep streamlining the cost structure of our base business; we're still on track to achieve non-GAAP net income and positive cash flows for full year 2025. As we said before in the press release about the acquisition, we anticipate remaining profitable on a non-GAAP basis and cash flow positive even through the period when navenibart is being developed. To wrap up, I take pride in how our team keeps focusing and executing as we strive to drive sustainable growth and bring meaningful improvements to patients' lives. Our solid results, along with disciplined operational and financial strategies, put us in position to seize future growth opportunities, reinforce our leadership in rare diseases, and keep delivering value for our shareholders. Operator, we're ready now to take your questions.
This is Jose calling in for Jessica. Regarding the 37% year-over-year increase in ORLADEYO net revenue, what portion came from volume, and what portion came from an improved paid rate or net price? Also, on that topic, what should our expectations be for gross to net during this quarter and as we move into 2026? And one more quick thing — with the competitive landscape getting more intense, how confident are you about keeping patient retention rates stable?
I can take that one first. Out of that 37% year-over-year figure, our volume growth has been quite consistent across time, but a significant share of it was driven by price, reflecting the paid rate improvement we talked about earlier in the year, especially within the Medicare segment. So volume is expanding at the rate we anticipated and at the rate required to reach $1 billion in peak revenue in 2029. On the question of patient retention amid new competition entering, as I said in the remarks, our retention has matched our existing trend exactly, with no impact whatsoever from the new products arriving in the market, and we anticipate that will remain the case.
Right. And I would simply mention that the reasoning there is that these individuals are actually very well managed; they're achieving control comparable to that of injectable medications, and they take a single daily tablet. So whatever in the world could they change to that would possibly be superior to that.
So the gap between gross and net remains roughly 15%, which is what we shared with everyone earlier in the year.
And next year in that 15% to 20%...
Right. Over the coming year, that figure is going to remain between 15% and 20%, and most likely it will land somewhat nearer to 15%.
I've got a question about the new prescriber figures. This makes two quarters straight, I believe, where you've come in above 60. I'm just wondering whether you have any feedback or market research that sheds light on why they're choosing to prescribe at this point? What's been the motivating factor lately that's driving these adds faster? And then, I suppose, could you give a bit more color on what the expected blended royalty rate would be in '26? I realize you're forecasting a step down as time goes on, but I'm just curious how we ought to think about it directionally going from '25 to '26.
Let me begin with — thank you, Laura. I'll begin with the prescriber data, and then I'll pass it to Babar for the royalties. So as far as the motivating factors, and we've talked about this previously, it's simply that physicians are growing increasingly comfortable with the long-term evidence, the real-world evidence for how well ORLADEYO works. What they now grasp is that ORLADEYO performs very well, just as well as injectable products for most patients. Either it works or it doesn't. And when patients don't get the benefit they need, they move on. So physicians truly are grasping that. That's the first piece. The second piece is our capacity to locate prescribers in this market and target them accurately, which means we can find physicians who have a smaller number of patients. So if you've got one HAE patient, we will find you, and ORLADEYO is turning into the treatment of choice for those doctors. Broadly, as we increase the number of physicians, we consistently observe a pretty equal balance between those smaller prescribers and the top 600 or so doctors who treat 50% of the market. So we keep chipping away at those top prescribers, and launch to date over 80% of those doctors have prescribed. So we're really thrilled to show this consistent progress expanding the number of prescribers.
One more point I want to make, Charlie: among even the highest prescribers, some doctors have yet to prescribe ORLADEYO. What has us really enthusiastic for next year is the pediatric approval, since these physicians see pediatric patients—lots of them—and nothing should keep them from choosing ORLADEYO for prophylaxis in those cases. That, we believe, will bring in still more new prescribers next year.
Absolutely. Regarding the royalty piece, we're happy to report that during this quarter we're crossing below the lower threshold, and that figure will keep declining. As shown in our prepared slides, the rate sits in the early — the blended rate sits in the early teens. And although no 2026 guidance has been provided, I can tell you that this rate will keep falling, since a cap applies to certain of those royalties once you reach $550 million. Yet as you might expect, when the time comes for us to give you guidance, once you run the numbers, it will be — it will keep going lower. And as we've stated, eventually it will land in single-digits once the OMERS liability is fully paid off.
Right, so with revenue increasing, our profitability keeps improving, and cash flow keeps coming in. So the financial outlook is really bright.
Congratulations on the advancement. We've got two questions for you. To start, regarding the new competitors, our key opinion leaders do point out that a few patients are moving from ORLADEYO to injectable options, yet those same doctors also tell us they anticipate ORLADEYO's market share will remain steady. So aside from this anecdotal input, and clearly you've emphasized the 60% retention at 1 year, can you provide any current data indicating ORLADEYO probably won't face much effect from these injectable newcomers? That's question one. Then question two concerns the pediatric HAE approval. With the PDUFA date coming up, perhaps you could help us grasp your perspective on the size of the opportunity and what commercial plan and groundwork are underway to ensure you fully capitalize on that pediatric expansion? Have many of these patients already been identified? Just give us a sense, as we head into the new year, of what expectations might be, including possibly some dormant patient demand.
Absolutely. Appreciate it, Stacy. On the new competitors, sure, naturally, a number of patients are moving off ORLADEYO since 40% of those starting ORLADEYO as new patients discontinue during the year. Previously, they may have moved to TAKHZYRO and HAEGARDA, whereas now they could be more inclined to go to certain new competitors; so that matches precisely what we anticipated. What we aren't observing, however, is any shift in how new patients are being prescribed to or any shift in our total retention figure; and concerning the evidence that gives us assurance about this, as I noted, Slide 8, we conducted our market research anew; we redid our extensive conjoint analysis and market simulation incorporating all the fresh details regarding new and upcoming rivals. And what emerges is no difference from our earlier iterations of this market research. It indicates that ORLADEYO remains — patients on ORLADEYO stay quite loyal, and we anticipate that will hold. Turning to the pediatric approval, we observe roughly 500 patients currently diagnosed with HAE below age 12. And merely around 40% of those patients right now are receiving or have, in a sense, within the prophylaxis area, tried prophylaxis. Thus we believe there's a chance both to expand prophylaxis usage among pediatrics and for switching, since an oral treatment matters greatly to many patients, yet it's especially vital for children with HAE. So regarding our approach, and Jon said earlier, the physicians who manage kids with HAE are typically the very same ones handling patients above age 12. So we're already visiting these doctors; we know who treats kids, and the team will be prepared to launch soon after approval.
I was hoping you could say more about why you've chosen to pull back on avoralstat for DME. Have you gotten an early peek at the Phase I results yet? And then, on the updated pipeline slide, there are undisclosed programs for rare diseases, at least the preclinical ones. Could you tell us a bit about what you're doing preclinically there and how near it may be to the clinic?
Yes, I'll handle that question. As for avoralstat, no, none of the data has been seen by us. We've only just enrolled the first cohort; therefore, this call is driven by focus and expense. With a late-stage product such as navenibart now in our pipeline, we must carve out room so we can fund it and carry it to the finish line. Those DME programs become very costly as you move further along in clinical development; and frankly, the expertise we have in rare disease isn't there for that area; so our view is that it belongs with someone who does possess that expertise. Then, about the undisclosed, we won't reveal what it is. It's early. It's exciting. But once it's ready to be shared, we'll have more information to share with you.
All right. And a fast one about Netherton. Has there been any conversation with regulators on your end, and have you built up a sense of what a pivotal program requirement could look like?
Yes, we have. It's not sufficient for us to reveal the pivotal program's design right now. I believe the main point — and Bill, feel free to fix this if I've got it wrong — is that the larger the treatment effect, the more favorable the choices available to us for moving quickly with this program. And we'll determine that as soon as data starts coming in. But it's too soon to forecast the pivotal program's design, so to speak. Is that accurate, Bill?
That’s quite reasonable. I believe that when we have proof of how the drug works in NS patients and that it is safe for people with NS, we will then hold thorough discussions with regulators regarding the path to approval.
Congratulations on the advancement. I have a few fast questions about Netherton. Could you elaborate on why enrollment has been slower, and what number of patients will be included in the first quarter data update next year? Also, do you expect to dose above 12 mg per kg? And I'm curious whether the subcu dose is still being investigated, or if IV dosing will be the path forward from here?
Sure, I'll handle the first portion. You can address the second. Our timeline shifted by just a quarter. So the program has only a minor delay; and as Bill mentioned, investigator enthusiasm is extremely high, particularly once they view the healthy volunteer data. We hadn't anticipated the drug reaching the target in healthy volunteers; so those results have been quite encouraging. And then, Bill, would you like to field the second part of the question?
Absolutely. Yes, we're looking into both subcutaneous and intravenous delivery. That work will keep going. And exploring larger doses is a possibility we're keeping available.
Congratulations on the momentum you've kept building this quarter. Picking up again on Netherton — could you say a bit more about what the PK/PD data are showing you across those first two portions of the trial that's underway? I'd also like to know what prompted the launch of Part 4, which as I understand it began just a few weeks ago. Then, on a separate note regarding ORLADEYO, I'm curious what you're observing when it comes to demand among the standard C1 inhibitor patient group. My recollection is that you previously pointed to that as a source of growth.
Bill, would you like to handle Netherton, and Charlie, could you cover ORLADEYO?
Right. So Netherton is a really interesting condition. The key issue is what's going on in the epidermis. There are no plasma or serum biomarkers that can be measured. Second, our inhibitor binds very tightly and is quite potent. And you need to consider how plasma concentration will relate to what happens in the epidermis. There might actually be a disconnect between how long the drug remains in the epidermis after it binds to the target versus how long it stays circulating in plasma. That said, we are of course measuring blood levels of the drug, and there's nothing surprising there. On that basis alone, we believe it's worth continuing to investigate dosing as infrequently as once every 2 weeks. But truly, what matters is looking at the disease effects. There are no pharmacodynamic markers available to measure. It comes down to the effects on the disease in patients who have Netherton, and when we reach that point. Just to clarify, we haven't revealed whether Part 3 or Part 4 has begun. Part 3 involves only a small number of subjects receiving short-term dosing. That's how it's designed. Part 4 allows for longer-term dosing, and we're eager to move through both of those.
Correct, and what we anticipate having available during Q1 is Part 3. Charlie?
Yeah. Brian, when it comes to C1 normal patients, since we launched, roughly one-third of the people taking ORLADEYO have fallen into that group, and Q3 reflected that same pattern. During Q2, as you may remember, we recorded an outstanding quarter for new patient starts — the strongest we've ever had. A further bolus of C1 normal patients came in Q2, since we put out some fresh data. Q3 resembled the consistent, elevated demand we've observed across the past 2 years, with approximately one-third of patients being C1 normal.
If I take a look at the revenue generated thus far in 2024 alongside your outlook, the implication is that quarter-over-quarter sales are going to decline, something that has never happened before. That kind of seasonal pattern hasn't shown up previously. So I was hoping you might elaborate a bit on what you're anticipating and what's behind it. Also, should we be prepared for this going forward, or is this a seasonality impact that happens only once?
Yes, Jon, this is a seasonality impact that happens only once, since we recently divested our European business. As a result, we're giving up somewhere between $10 million and $15 million in revenue that we would have brought in otherwise. That means when next year comes around, Q4 will not show a decline.
Yes.
John here, filling in for Serge today. I just wanted to ask about pediatric ORLADEYO, given the review that's underway and the PDUFA coming in mid-December. I'm just wondering whether you've noticed any effects from the government shutdown, if you've been receiving ongoing feedback from the FDA, and if you still expect them to hit that PDUFA. Then, assuming the product becomes available, what are your expectations for how the payer landscape will shape up in this segment? And might you expect a bolus of patients to start early once the product launches?
I'll handle the first part. Charlie, you take the second. As for our interactions with FDA, the PDUFA date is getting closer, and we're working through the sorts of things you'd expect to be working through at this stage, late in the review process. So nothing we're seeing raises concern about the government shutdown — that could change, but as of where we stand today, nothing we're seeing does.
John, regarding the payer situation, we're in a very strong position with payers for ORLADEYO, and we anticipate the peds indication will fit seamlessly into that. So there's nothing unusual happening on the payer side. When it comes to the bolus of patients, we're aware there's significant anticipation surrounding this product. I'm sure we'll provide an update once we've launched and gotten product into the market — we'll give you an update in 2026 on how quickly patient growth is progressing.
I'd like to ask about Netherton syndrome, and also about the 12-milligram per kg IV dosing — by the way, the biomarker data is really impressive. What sort of safety profile are you observing in the patient — in the healthy volunteer data? Then too, with regard to the first quarter, the Part 3 data. So perhaps you could outline what we ought to anticipate from that 1Q '26 data update coming out of Part 3? And quickly, just some housekeeping items on ORLADEYO. I realize you touched on a few of these comments, but I did want to verify with the actual numbers on the retention rate — are we still roughly at 60% — and the pay rate, which I believe last quarter we said might reach by year-end 82% to 83%. Does that remain the case? And finally, the patient segment, 50% switch from other prophy, is that unchanged as well?
All right. So Bill, why don't you handle the safety and the design of the Part 3? And then Charlie, you can handle the ORLADEYO.
Okay, regarding safety in healthy volunteers, what I can really tell you is that it has been quite safe up to this point — very safe, in fact, and well tolerated. With repeated administration of the drug, including at the dose you brought up, we have not seen any safety signals appear. That is genuinely encouraging. As for what Part 3 might show, I'd note that in that part the drug is given for a very brief period. We are doing pioneering work in clinical science and in studying Netherton syndrome with an injectable agent. So how much time is needed before an effect shows up is something we will find out. At this point, I simply don't know. Whether that brief period of treatment will be sufficient for us to observe an effect — I can't say. Should we see one, that would be extremely encouraging. Should we not, then we would simply administer the drug for a longer stretch and perhaps raise the dose. So my advice would be to keep expectations modest about what short-term dosing in a small number of Netherton patients may reveal. Naturally, safety will be under scrutiny; we will gain considerable knowledge, and we look forward to continuing dosing into Part 4 of the trial. The kinds of parameters you'd assess are fairly self-evident — itch, pain, redness of the skin, and similar things.
And Bill, in Part 3 we're trying out several different doses. So once we have that, we'll begin narrowing down what we'd like to examine in Part 4. Is that accurate?
It's the first step for more extensive testing in Part 4.
Great. Charlie?
And Gena, regarding the ORLADEYO figures — yes, our retention rate matches precisely what we've observed across the past several years; 60% of patients who begin ORLADEYO reach one year. And everything Q3 showed us indicates we're squarely on track with that very same number. On the paid rate, we closed Q3 at 82%, which is just about where we anticipated being; for Q4, it wouldn't shock me if we finished nearer to 81%, or even 80%. Usually, during the year's second half, the paid rate begins falling off since we have so many new patients arriving and fewer chances to move people off long-term free product onto paid product. That chance arrives in Q1 and into early Q2 of the new year. So we're exactly where we need to be, and we anticipate many of those patients shifting to paid therapy earlier in 2026. Then concerning where patient business originates — yes, the same general patterns hold, with close to 50% of people switching from other prophy history with other prophy products, and then additional patients moving from acute only over to prophy. And then a solid number of patients, from what we can best determine, are beginning ORLADEYO as their very first HAE treatment ever, since more of those are newly diagnosed patients.
Absolutely. We considered wrapping up with the Rolling Stones — this would be the final occasion — yet we decided against it. Still, allow me to share this: serving as the leader of BioCryst's workforce for close to 20 years has been a privilege. I take pride in what we constructed, in what we achieved as a group, and I feel tremendous enthusiasm and assurance watching this team carry the company forward by bringing ever more novel therapies to people battling uncommon illnesses, since within our field, that is the way genuine worth gets generated. So, thanks for taking an interest in our organization, and I hope your day is wonderful.
Appreciate it. That brings the call to a close. Thanks for joining us for today's presentation. You're welcome to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete BioCryst Pharmaceuticals, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to BioCryst Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.